{{Rsnum
|rsid=1809529
|Gene=SLC6A11
|Chromosome=3
|position=10835926
|Orientation=plus
|GMAF=0.4587
|Gene_s=SLC6A11
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 43.8 | 45.5 | 10.7
| HCB | 32.8 | 46.7 | 20.4
| JPT | 35.4 | 41.6 | 23.0
| YRI | 6.8 | 32.7 | 60.5
| ASW | 12.5 | 37.5 | 50.0
| CHB | 32.8 | 46.7 | 20.4
| CHD | 28.4 | 54.1 | 17.4
| GIH | 13.9 | 43.6 | 42.6
| LWK | 1.8 | 47.3 | 50.9
| MEX | 50.0 | 41.4 | 8.6
| MKK | 14.1 | 43.6 | 42.3
| TSI | 32.7 | 44.6 | 22.8
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=22491018
|Trait=None
|Title=Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis.
|RiskAllele=
|Pval=3E-7
|OR=0.2800
|ORtxt=None
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}